Free Trial

Calamos Advisors LLC Makes New $490,000 Investment in Lifevantage Corporation (NASDAQ:LFVN)

Lifevantage logo with Medical background

Calamos Advisors LLC acquired a new stake in shares of Lifevantage Corporation (NASDAQ:LFVN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 33,576 shares of the company's stock, valued at approximately $490,000. Calamos Advisors LLC owned about 0.27% of Lifevantage as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LFVN. Cannon Global Investment Management LLC purchased a new position in Lifevantage during the 1st quarter valued at approximately $156,000. Cambridge Investment Research Advisors Inc. grew its holdings in Lifevantage by 23.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 12,867 shares of the company's stock valued at $188,000 after buying an additional 2,421 shares in the last quarter. Hillsdale Investment Management Inc. grew its holdings in Lifevantage by 7.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company's stock valued at $258,000 after buying an additional 1,000 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Lifevantage during the 4th quarter valued at approximately $282,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Lifevantage during the 4th quarter valued at approximately $284,000. Hedge funds and other institutional investors own 35.32% of the company's stock.

Lifevantage Price Performance

Shares of NASDAQ LFVN traded up $0.53 during mid-day trading on Tuesday, hitting $14.12. 166,315 shares of the company's stock traded hands, compared to its average volume of 155,426. The company's 50-day moving average is $12.59 and its two-hundred day moving average is $15.89. The company has a market capitalization of $177.77 million, a P/E ratio of 20.46 and a beta of 0.43. Lifevantage Corporation has a 1 year low of $5.22 and a 1 year high of $27.38.

Lifevantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. Lifevantage had a return on equity of 34.67% and a net margin of 4.12%. The firm had revenue of $58.44 million for the quarter, compared to analyst estimates of $60.99 million.

Lifevantage Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 30th were given a dividend of $0.045 per share. This is a boost from Lifevantage's previous quarterly dividend of $0.04. This represents a $0.18 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend was Friday, May 30th. Lifevantage's dividend payout ratio (DPR) is currently 26.09%.

Insiders Place Their Bets

In related news, CFO Carl Aure sold 2,746 shares of the firm's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $13.39, for a total transaction of $36,768.94. Following the sale, the chief financial officer owned 133,303 shares in the company, valued at approximately $1,784,927.17. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 20.65% of the company's stock.

Lifevantage Profile

(Free Report)

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

Recommended Stories

Institutional Ownership by Quarter for Lifevantage (NASDAQ:LFVN)

Should You Invest $1,000 in Lifevantage Right Now?

Before you consider Lifevantage, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifevantage wasn't on the list.

While Lifevantage currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines